CTL-119

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameCTL-119
Drug Alias NameCTL119CTL-119huCART19huCTL019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Pennsylvania Clinical Cell and Vaccine Production FacilityNational Cancer InstituteUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A